News
ALMS
7.16
+0.85%
0.06
Weekly Report: what happened at ALMS last week (0914-0918)?
Weekly Report · 09/21 09:18
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 09/18 14:20
Weekly Report: what happened at ALMS last week (0907-0911)?
Weekly Report · 09/14 09:19
Alumis (ALMS), What Is Behind The Fresh Attention?
Simply Wall St · 09/11 20:22
Thursday 9/10 Insider Buying Report: ALMS, PRTS
NASDAQ · 09/10 14:44
Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
TipRanks · 09/09 17:15
Alumis (ALMS) Is Down 49.1% After Mixed LUMUS Trial Data Reshapes Envudeucitinib’s Precision-Medicine Path
Simply Wall St · 09/07 19:28
Weekly Report: what happened at ALMS last week (0831-0904)?
Weekly Report · 09/07 09:18
Alumis (ALMS) After The Lupus Trial Miss, Is A 3.3x P B Premium Too Rich?
Simply Wall St · 09/04 07:32
Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)
TipRanks · 09/03 14:30
Alumis Cut to Neutral From Buy by Guggenheim
Dow Jones · 09/03 13:46
Guggenheim Downgrades Alumis to Neutral
Benzinga · 09/03 13:36
Alumis downgraded at Guggenheim after trial setback for SLE candidate
Seeking Alpha · 09/03 12:57
Alumis downgraded to Neutral from Buy at Guggenheim
TipRanks · 09/03 09:40
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
TipRanks · 09/03 09:40
Alumis Is Maintained at Outperform by Oppenheimer
Dow Jones · 09/02 17:02
Alumis Price Target Cut to $37.00/Share From $55.00 by Oppenheimer
Dow Jones · 09/02 17:02
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Benzinga · 09/02 16:51
Alumis rises 10.7%
TipRanks · 09/02 16:05
Midday Fly By: Dell reports sharp Q2 beat, Nvidia in talks to buy Hugging Face
TipRanks · 09/02 15:55
More
Webull provides a variety of real-time ALMS stock news. You can receive the latest news about Alumis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.